A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non--Small Cell Lung Cancer with KRAS G12C Mutation.

PI: Dott. Giuseppe Lo Russo 

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. 

Eligible patients will be randomized 1:1 to: 

• Investigational arm (Cohort 3): Adagrasib + pembrolizumab  

• Comparator arm (Cohort 4): Pembrolizumab